Adaptimmune Therapeutics PLC
ADAP0.055USD
0.0000.00%
收盤 03/30, 16:00（美東）報價延遲15分鐘
87.31M總市值
虧損本益比TTM
關於 Adaptimmune Therapeutics PLC 公司
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Adaptimmune Therapeutics PLC簡介
公司代碼ADAP
公司名稱Adaptimmune Therapeutics PLC
上市日期May 06, 2015
CEORawcliffe (Adrian George)
員工數量506
證券類型Depository Receipt
年結日May 06
公司地址60 Jubilee Avenue
城市ABINGDON
上市交易所NASDAQ Capital Market Consolidated
國家United Kingdom
郵編OX14 4RX
電話441235430000
網址https://www.adaptimmune.com/
公司代碼ADAP
上市日期May 06, 2015
CEORawcliffe (Adrian George)
Adaptimmune Therapeutics PLC公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+65.65%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kristen M. Hege, M.D.
Dr. Kristen M. Hege, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Andrew Allen, M.D., Ph.D.
Dr. Andrew Allen, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Priti Hegde, Ph.D.
Dr. Priti Hegde, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+65.65%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 3月29日 週日
更新時間: 3月29日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Alpha Architect, LLC
0.30%
Menzel (Garry E)
0.23%
Rathbones Investment Management Limited
0.16%
Rawcliffe Adrian
0.15%
XTX Markets LLC
0.13%
其他
99.02%
持股股東
持股股東
佔比
Alpha Architect, LLC
0.30%
Menzel (Garry E)
0.23%
Rathbones Investment Management Limited
0.16%
Rawcliffe Adrian
0.15%
XTX Markets LLC
0.13%
其他
99.02%
股東類型
持股股東
佔比
Individual Investor
0.63%
Investment Advisor
0.33%
Investment Advisor/Hedge Fund
0.21%
Venture Capital
0.13%
Research Firm
0.02%
其他
98.68%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
165
42.25M
57.79%
-8.12K
2025Q3
183
42.26M
58.51%
-57.25M
2025Q2
189
116.07M
65.05%
-1.37M
2025Q1
186
117.46M
62.78%
-44.42M
2024Q4
186
127.90M
58.86%
-11.67M
2024Q3
189
154.60M
64.35%
-2.20M
2024Q2
192
156.54M
67.34%
-7.97M
2024Q1
203
164.83M
67.18%
-6.80M
2023Q4
199
145.59M
71.95%
-5.54M
2023Q3
217
150.77M
70.44%
+3.59M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Alpha Architect, LLC
800.00K
0.3%
--
--
Sep 30, 2025
Menzel (Garry E)
611.22K
0.23%
+401.29K
+191.15%
Apr 11, 2025
Rathbones Investment Management Limited
432.82K
0.16%
--
--
Sep 30, 2025
Rawcliffe Adrian
395.23K
0.15%
+219.59K
+125.03%
Apr 11, 2025
Bertrand William C Jr
198.89K
0.07%
+59.86K
+43.05%
Apr 11, 2025
Lunger (John)
170.89K
0.06%
+59.86K
+53.91%
Apr 11, 2025
Norry (Elliot)
133.26K
0.05%
+66.41K
+99.32%
Apr 11, 2025
Piccina (Cintia)
111.07K
0.04%
+94.24K
+559.70%
Apr 11, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
ActivePassive International Equity ETF
0%
Fidelity Enhanced Small Cap ETF
0%
SPDR S&P International Small Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
ActivePassive International Equity ETF
佔比0%
Fidelity Enhanced Small Cap ETF
佔比0%
SPDR S&P International Small Cap ETF
佔比0%
Invesco NASDAQ Future Gen 200 ETF
佔比0%
SPDR Portfolio Developed World ex-US ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
